Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the primary driver for any regulatory delay in Lundbeck's acquisition of Longboard Pharmaceuticals?
Antitrust Concerns • 25%
Financial Discrepancies • 25%
Intellectual Property Issues • 25%
Other • 25%
Official reports or statements from regulatory bodies or involved companies
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 11:18 AM
Denmark's Lundbeck has announced its acquisition of Longboard Pharmaceuticals in a deal valued at $2.6 billion equity value. The acquisition, which will be executed at $60 per share in cash, represents a 77% premium to Longboard's volume-weighted average price (VWAP). The total transaction value is approximately $2.5 billion net of cash. The deal has been unanimously approved by the boards of both companies and is expected to close in the fourth quarter of 2024, pending regulatory approvals. This strategic acquisition aims to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments. Centerview LLC acted as the financial advisor for the deal. Longboard's stock surged by over 50% in pre-market trading following the announcement. Longboard's Phase 3 asset for Dravet syndrome was a core interest for Lundbeck.
View original story
Regulatory hurdles • 25%
Financing issues • 25%
Shareholder opposition • 25%
Other • 25%
Yes • 50%
No • 50%
On time (by Q4 2024) • 25%
Delayed to Q1 2025 • 25%
Delayed to Q2 2025 or later • 25%
Deal Cancelled • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive • 25%
Neutral • 25%
Negative • 25%
Mixed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant enhancement in neuroscience pipeline • 25%
Moderate enhancement • 25%
No significant change • 25%
Negative impact • 25%
Regulatory issues • 25%
Financial issues • 25%
Operational challenges • 25%
No delay • 25%
No changes • 25%
Minor changes • 25%
Major changes • 25%
Complete overhaul • 25%
Increase > 10% • 25%
Increase 0-10% • 25%
Decrease 0-10% • 25%
Decrease > 10% • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Longboard's stock remains stable • 25%
Other • 25%
Lundbeck's stock rises over 5% • 25%
Lundbeck's stock falls over 5% • 25%